PF-Atlas › Clinical Trials › NCT05975983

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

INS018_055 · Phase 2

Registry ID
NCT05975983
Phase
Phase 2
Status
Recruiting
Drug / intervention
INS018_055
Sponsor
InSilico Medicine Hong Kong Limited
Start
2024-02-08
Enrollment
40
Locations
12

About this trial

The purpose of this revised Phase IIa study is to demonstrate safety of INS018\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).

View NCT05975983 on ClinicalTrials.gov →

Explore related

All INS018_055 trialsAll IPF trials

Related trials

INS018_055 — NCT05938920INS018_055 — NCT05154240
Medical disclaimer. This page summarizes public trial data for NCT05975983 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.